Methods	Multicentre, randomised, double-blind, placebo-controlled, parallel-group. Single dose to treat single attack Medication administered when migraine headache pain was of moderate to severe intensity Assessments at 10, 20, 30, 60, 90, 120, 180, and 240 minutes after dosing Rescue medication (excluding ergotamine-containing therapy) was available after 4 h for inadequate relief of symptoms
Participants	Aged 18 to 55 years, meeting IHS criteria for migraine (1988) with or without aura. At least 1-year history of migraine (untreated severity ≥ moderate) with an average of 1 to 6 attacks per month Participants were excluded if they had previously received subcutaneous sumatriptan Migraine prophylactic therapy stopped at least 2 weeks before the administration of study treatment No ergotamine-containing preparations within 24 h, or analgesics within 6 h of receiving study medication N = 335 M 47, F 288 (86%) Mean age 38 years Without aura 89%
Interventions	Sumatriptan 6 mg, n = 47 Naratriptan 0.5 mg, n = 60 Naratriptan 1 mg, n = 55 Naratriptan 2.5 mg, n = 42 Naratriptan 5 mg, n = 34 Naratriptan 10 mg, n = 34 Placebo, n = 63
Outcomes	Headache relief (at 1 and 2 h) Pain-free (at 2 h) Improvement in nausea, vomiting, and photo/phonophobia at 2 h Presence of functional disability at 2 h Use of rescue medication Adverse events Withdrawals
Notes	Oxford Quality Score: R1, DB1, W1. Total = 3.
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported
Study size	High risk	Some treatment groups 50 to 200 participants, others <50 participants